Lansoprazole heals erosive reflux esophagitis resistant to histamine H2- receptor antagonist therapy

S. J. Sontag, D. G. Kogut, R. Fleischmann, D. R. Campbell, J. Richter, M. Robinson, M. McFarland, S. Sabesin, Glen Lehman, D. Castell

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Purpose: We conducted a randomized, double-blind, multicenter clinical trial to determine whether lansoprazole was superior to continued therapy with histamine H2-receptor antagonist therapy in healing erosive reflux esophagitis. Methods: Investigators from nine medical centers enrolled 159 patients with endoscopically documented esophageal erosions and/or ulcers that had failed to heal with 12 or more wk of at least standard dosages of histamine H2-receptor antagonist therapy. Patients received ranitidine 150 mg b.i.d. for 8 wk or lansoprazole 30 mg for 4 wk followed by either lansoprazole 30 mg or lansoprazole 60 mg for another 4 wk of treatment. Patients underwent endoscopy at screening and at weeks 2, 4, and 8. Results: At 2, 4, and 8 wk of therapy, healing rates were significantly higher in the lansoprazole group compared with the ranitidine group (p <0.001). By 8 wk, 84% of the lansoprazole group were healed as opposed to only 32% of the ranitidine group. Lansoprazole was superior to ranitidine in providing relief of upper abdominal burning and daytime heartburn (p <0.001) and reducing the need for antacids (p <0.001). Lansoprazole patients had less interference with sleep and less daytime drowsiness than ranitidine patients (p = 0.05). The percentages of patients with adverse events were similar in both groups. Fasting serum gastrin levels at weeks 4 and 8 were significantly higher in the lansoprazole group compared with the ranitidine group. Conclusion: Eight weeks of lansoprazole therapy is safe, superior to continued ranitidine therapy, and effective in healing more than 80% of patients with erosive reflux esophagitis previously resistant to histamine H2-receptor antagonist therapy.

Original languageEnglish (US)
Pages (from-to)429-437
Number of pages9
JournalAmerican Journal of Gastroenterology
Volume92
Issue number3
StatePublished - 1997
Externally publishedYes

Fingerprint

Histamine H2 Antagonists
Lansoprazole
Peptic Esophagitis
Ranitidine
Therapeutics
Heartburn
Antacids
Sleep Stages
Gastrins
Endoscopy
Multicenter Studies
Ulcer
Fasting
Sleep
Research Personnel
Clinical Trials

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Sontag, S. J., Kogut, D. G., Fleischmann, R., Campbell, D. R., Richter, J., Robinson, M., ... Castell, D. (1997). Lansoprazole heals erosive reflux esophagitis resistant to histamine H2- receptor antagonist therapy. American Journal of Gastroenterology, 92(3), 429-437.

Lansoprazole heals erosive reflux esophagitis resistant to histamine H2- receptor antagonist therapy. / Sontag, S. J.; Kogut, D. G.; Fleischmann, R.; Campbell, D. R.; Richter, J.; Robinson, M.; McFarland, M.; Sabesin, S.; Lehman, Glen; Castell, D.

In: American Journal of Gastroenterology, Vol. 92, No. 3, 1997, p. 429-437.

Research output: Contribution to journalArticle

Sontag, SJ, Kogut, DG, Fleischmann, R, Campbell, DR, Richter, J, Robinson, M, McFarland, M, Sabesin, S, Lehman, G & Castell, D 1997, 'Lansoprazole heals erosive reflux esophagitis resistant to histamine H2- receptor antagonist therapy', American Journal of Gastroenterology, vol. 92, no. 3, pp. 429-437.
Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Robinson M et al. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2- receptor antagonist therapy. American Journal of Gastroenterology. 1997;92(3):429-437.
Sontag, S. J. ; Kogut, D. G. ; Fleischmann, R. ; Campbell, D. R. ; Richter, J. ; Robinson, M. ; McFarland, M. ; Sabesin, S. ; Lehman, Glen ; Castell, D. / Lansoprazole heals erosive reflux esophagitis resistant to histamine H2- receptor antagonist therapy. In: American Journal of Gastroenterology. 1997 ; Vol. 92, No. 3. pp. 429-437.
@article{fa22160565f841fd8945ec809798c14e,
title = "Lansoprazole heals erosive reflux esophagitis resistant to histamine H2- receptor antagonist therapy",
abstract = "Purpose: We conducted a randomized, double-blind, multicenter clinical trial to determine whether lansoprazole was superior to continued therapy with histamine H2-receptor antagonist therapy in healing erosive reflux esophagitis. Methods: Investigators from nine medical centers enrolled 159 patients with endoscopically documented esophageal erosions and/or ulcers that had failed to heal with 12 or more wk of at least standard dosages of histamine H2-receptor antagonist therapy. Patients received ranitidine 150 mg b.i.d. for 8 wk or lansoprazole 30 mg for 4 wk followed by either lansoprazole 30 mg or lansoprazole 60 mg for another 4 wk of treatment. Patients underwent endoscopy at screening and at weeks 2, 4, and 8. Results: At 2, 4, and 8 wk of therapy, healing rates were significantly higher in the lansoprazole group compared with the ranitidine group (p <0.001). By 8 wk, 84{\%} of the lansoprazole group were healed as opposed to only 32{\%} of the ranitidine group. Lansoprazole was superior to ranitidine in providing relief of upper abdominal burning and daytime heartburn (p <0.001) and reducing the need for antacids (p <0.001). Lansoprazole patients had less interference with sleep and less daytime drowsiness than ranitidine patients (p = 0.05). The percentages of patients with adverse events were similar in both groups. Fasting serum gastrin levels at weeks 4 and 8 were significantly higher in the lansoprazole group compared with the ranitidine group. Conclusion: Eight weeks of lansoprazole therapy is safe, superior to continued ranitidine therapy, and effective in healing more than 80{\%} of patients with erosive reflux esophagitis previously resistant to histamine H2-receptor antagonist therapy.",
author = "Sontag, {S. J.} and Kogut, {D. G.} and R. Fleischmann and Campbell, {D. R.} and J. Richter and M. Robinson and M. McFarland and S. Sabesin and Glen Lehman and D. Castell",
year = "1997",
language = "English (US)",
volume = "92",
pages = "429--437",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Lansoprazole heals erosive reflux esophagitis resistant to histamine H2- receptor antagonist therapy

AU - Sontag, S. J.

AU - Kogut, D. G.

AU - Fleischmann, R.

AU - Campbell, D. R.

AU - Richter, J.

AU - Robinson, M.

AU - McFarland, M.

AU - Sabesin, S.

AU - Lehman, Glen

AU - Castell, D.

PY - 1997

Y1 - 1997

N2 - Purpose: We conducted a randomized, double-blind, multicenter clinical trial to determine whether lansoprazole was superior to continued therapy with histamine H2-receptor antagonist therapy in healing erosive reflux esophagitis. Methods: Investigators from nine medical centers enrolled 159 patients with endoscopically documented esophageal erosions and/or ulcers that had failed to heal with 12 or more wk of at least standard dosages of histamine H2-receptor antagonist therapy. Patients received ranitidine 150 mg b.i.d. for 8 wk or lansoprazole 30 mg for 4 wk followed by either lansoprazole 30 mg or lansoprazole 60 mg for another 4 wk of treatment. Patients underwent endoscopy at screening and at weeks 2, 4, and 8. Results: At 2, 4, and 8 wk of therapy, healing rates were significantly higher in the lansoprazole group compared with the ranitidine group (p <0.001). By 8 wk, 84% of the lansoprazole group were healed as opposed to only 32% of the ranitidine group. Lansoprazole was superior to ranitidine in providing relief of upper abdominal burning and daytime heartburn (p <0.001) and reducing the need for antacids (p <0.001). Lansoprazole patients had less interference with sleep and less daytime drowsiness than ranitidine patients (p = 0.05). The percentages of patients with adverse events were similar in both groups. Fasting serum gastrin levels at weeks 4 and 8 were significantly higher in the lansoprazole group compared with the ranitidine group. Conclusion: Eight weeks of lansoprazole therapy is safe, superior to continued ranitidine therapy, and effective in healing more than 80% of patients with erosive reflux esophagitis previously resistant to histamine H2-receptor antagonist therapy.

AB - Purpose: We conducted a randomized, double-blind, multicenter clinical trial to determine whether lansoprazole was superior to continued therapy with histamine H2-receptor antagonist therapy in healing erosive reflux esophagitis. Methods: Investigators from nine medical centers enrolled 159 patients with endoscopically documented esophageal erosions and/or ulcers that had failed to heal with 12 or more wk of at least standard dosages of histamine H2-receptor antagonist therapy. Patients received ranitidine 150 mg b.i.d. for 8 wk or lansoprazole 30 mg for 4 wk followed by either lansoprazole 30 mg or lansoprazole 60 mg for another 4 wk of treatment. Patients underwent endoscopy at screening and at weeks 2, 4, and 8. Results: At 2, 4, and 8 wk of therapy, healing rates were significantly higher in the lansoprazole group compared with the ranitidine group (p <0.001). By 8 wk, 84% of the lansoprazole group were healed as opposed to only 32% of the ranitidine group. Lansoprazole was superior to ranitidine in providing relief of upper abdominal burning and daytime heartburn (p <0.001) and reducing the need for antacids (p <0.001). Lansoprazole patients had less interference with sleep and less daytime drowsiness than ranitidine patients (p = 0.05). The percentages of patients with adverse events were similar in both groups. Fasting serum gastrin levels at weeks 4 and 8 were significantly higher in the lansoprazole group compared with the ranitidine group. Conclusion: Eight weeks of lansoprazole therapy is safe, superior to continued ranitidine therapy, and effective in healing more than 80% of patients with erosive reflux esophagitis previously resistant to histamine H2-receptor antagonist therapy.

UR - http://www.scopus.com/inward/record.url?scp=19244380749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19244380749&partnerID=8YFLogxK

M3 - Article

C2 - 9068463

AN - SCOPUS:19244380749

VL - 92

SP - 429

EP - 437

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 3

ER -